In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
News|Podcasts|May 7, 2026
Pharma Pulse: GLP-1 Momentum Builds While Lilly Expands Genetic Medicine Manufacturing
Author(s)Stephen Appezzato
In this week's Pharma Pulse, Eli Lilly opens its new genetic medicine plant, Bayer acquires Perfuse Therapeutics, and more.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest insights shaping patient access, supply chain dynamics, and healthcare innovation. I’m your host—let’s get into today’s headlines.
First up, Eli Lilly has opened its first dedicated
Next, GLP-1 therapies accounted for 8 out of every 100 prescriptions filled in March 2026, according to
In
And finally, the FDA has authorized the first fruit-flavored electronic nicotine delivery system products, a decision that signals a major
That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit
You can catch Pharma Pulse directly on
Advertisement
Related to this article
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.
A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.
DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.
Advertisement
Advertisement